Human Genome Sciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1992-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.hgsi.com
Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Human Genome Sciences Inc.
- Registration Number
- NCT00092924
- Locations
- 🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States
🇺🇸Rush Medical College, Chicago, Illinois, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
Phase 2
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 283
- Registration Number
- NCT00071812
- Locations
- 🇺🇸
Wallace Rheumatic Disease Center, Los Angeles, California, United States
🇺🇸Evergreen Clinical Reserach, Edmonds, Washington, United States
🇺🇸Marshfield Medical Research Foundation, Wausau, Wisconsin, United States
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
Phase 2
Completed
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2003-10-28
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 449
- Registration Number
- NCT00071487
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath